Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Gains from Investment Securities (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Gains from Investment Securities for 16 consecutive years, with $1.6 million as the latest value for Q2 2025.

  • On a quarterly basis, Gains from Investment Securities fell 77.34% to $1.6 million in Q2 2025 year-over-year; TTM through Jun 2025 was $1.6 million, a 76.96% decrease, with the full-year FY2024 number at $18.1 million, down 1.11% from a year prior.
  • Gains from Investment Securities was $1.6 million for Q2 2025 at Gyre Therapeutics, up from $952000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $18.3 million in Q4 2023 to a low of -$3000.0 in Q1 2024.
  • A 5-year average of $5.7 million and a median of $2.8 million in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 100.02% in 2024, then soared 31833.33% in 2025.
  • Gyre Therapeutics' Gains from Investment Securities stood at $2.6 million in 2021, then soared by 233.33% to $8.7 million in 2022, then soared by 110.64% to $18.3 million in 2023, then fell by 1.11% to $18.1 million in 2024, then plummeted by 90.94% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Gains from Investment Securities are $1.6 million (Q2 2025), $952000.0 (Q1 2025), and $18.1 million (Q4 2024).